Imvamune Vaccine Information Sheet for Healthcare Providers - How does the IMVAMUNE vaccine protect against mpox?

There is a lack of evidence of safety and efficacy of IMVAMUNE pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) in this group, though indirect evidence of clinical testing of other vaccine types indicates that IMVAMUNE components are well tolerated in recipients under 18 years of age. [...] Are you allergic or do you have a confirmed allergy If you are allergic to tromethamine (trometamol, Tris), benzonase, gentamicin or to tromethamine2 (trometamol, Tris), benzonase3, ciprofloxacin, consult with your health care provider about whether to receive the gentamicin4 or ciprofloxacin4 which are contained IMVAMUNE vaccine. [...] in the IMVAMUNE vaccine? Do you have a suspected but unproven allergy to a If “yes”, you may receive the IMVAMUNE vaccine. [...] How is the vaccine administered? The vaccine is administered by subcutaneous injection, preferably in over the area of the deltoid muscle. [...] What are the risks of the vaccine? • IMVAMUNE vaccine has been authorized by Health Canada for active immunization against smallpox, mpox and related orthopoxvirus infection and disease under the provision of the Extraordinary Use New Drug (EUND) regulations in adults 18 years of age and older determined to be at high risk for exposure.